Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,698 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.
Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, Bishop T, Benitez J, Rivas C, Bignon YJ, Chang-Claude J, Hamann U, Cornelisse CJ, Devilee P, Beckmann MW, Nestle-Krämling C, Daly PA, Haites N, Varley J, Lalloo F, Evans G, Maugard C, Meijers-Heijboer H, Klijn JG, Olah E, Gusterson BA, Pilotti S, Radice P, Scherneck S, Sobol H, Jacquemier J, Wagner T, Peto J, Stratton MR, McGuffog L, Easton DF; Breast Cancer Linkage Consortium. Lakhani SR, et al. Among authors: evans g. Clin Cancer Res. 2005 Jul 15;11(14):5175-80. doi: 10.1158/1078-0432.CCR-04-2424. Clin Cancer Res. 2005. PMID: 16033833
Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update.
Ginsburg O, Ghadirian P, Lubinski J, Cybulski C, Lynch H, Neuhausen S, Kim-Sing C, Robson M, Domchek S, Isaacs C, Klijn J, Armel S, Foulkes WD, Tung N, Moller P, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group. Ginsburg O, et al. Breast Cancer Res Treat. 2009 Mar;114(1):127-35. doi: 10.1007/s10549-008-9977-5. Epub 2008 May 16. Breast Cancer Res Treat. 2009. PMID: 18483851 Free PMC article.
Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom.
Shanley S, McReynolds K, Ardern-Jones A, Ahern R, Fernando I, Yarnold J, Evans G, Eccles D, Hodgson S, Ashley S, Ashcroft L, Tutt A, Bancroft E, Short S, Gui G; Breast Unit of the Royal Marsden NHS Foundation Trust; Barr L, Baildam A, Howell A, Royle G, Pierce L, Easton D, Eeles R. Shanley S, et al. Among authors: evans g. Clin Cancer Res. 2006 Dec 1;12(23):7025-32. doi: 10.1158/1078-0432.CCR-06-1244. Clin Cancer Res. 2006. PMID: 17145824
Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom.
Shanley S, McReynolds K, Ardern-Jones A, Ahern R, Fernando I, Yarnold J, Evans G, Eccles D, Hodgson S, Ashley S, Ashcroft L, Tutt A, Bancroft E, Short S, Smith I, Gui G; Royal Marsden NHS Foundation Trust; Barr L, Baildam A, Howell A, Royle G, Pierce L, Easton D, Eeles R. Shanley S, et al. Among authors: evans g. Clin Cancer Res. 2006 Dec 1;12(23):7033-8. doi: 10.1158/1078-0432.CCR-06-1246. Clin Cancer Res. 2006. PMID: 17145825
No evidence that GATA3 rs570613 SNP modifies breast cancer risk.
Johnatty SE, Couch FJ, Fredericksen Z, Tarrell R, Spurdle AB, Beesley J, Chen X; kConFab Investigators; AOCS Group; Swedish BRCA1 and BRCA2 Study Collaborators; Gschwantler-Kaulich D, Singer CF, Fuerhauser C, Fink-Retter A, Domchek SM, Nathanson KL, Pankratz VS, Lindor NM, Godwin AK, Caligo MA, Hopper J, Southey MC, Giles GG, Justenhoven C, Brauch H, Hamann U, Ko YD, Heikkinen T, Aaltonen K, Aittomäki K, Blomqvist C, Nevanlinna H, Hall P, Czene K, Liu J, Peock S, Cook M, Platte R, Gareth Evans D, Lalloo F, Eeles R, Pichert G, Eccles D, Davidson R, Cole T, Cook J, Douglas F, Chu C, Hodgson S, Paterson J, Hogervorst FB, Rookus MA, Seynaeve C, Wijnen J, Vreeswijk M, Ligtenberg M, van der Luijt RB, van Os TA, Gille HJ, Blok MJ; HEBON; Issacs C, Humphreys MK, McGuffog L, Healey S, Sinilnikova O, Antoniou AC, Easton DF, Chenevix-Trench G; Breast Cancer Association Consortium and Consortium of Investigators of Modifiers of BRCA1/2. Johnatty SE, et al. Breast Cancer Res Treat. 2009 Sep;117(2):371-9. doi: 10.1007/s10549-008-0257-1. Epub 2008 Dec 11. Breast Cancer Res Treat. 2009. PMID: 19082709 Free PMC article.
DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers.
Osorio A, Milne RL, Kuchenbaecker K, Vaclová T, Pita G, Alonso R, Peterlongo P, Blanco I, de la Hoya M, Duran M, Díez O, Ramón Y Cajal T, Konstantopoulou I, Martínez-Bouzas C, Andrés Conejero R, Soucy P, McGuffog L, Barrowdale D, Lee A; SWE-BRCA; Arver B, Rantala J, Loman N, Ehrencrona H, Olopade OI, Beattie MS, Domchek SM, Nathanson K, Rebbeck TR, Arun BK, Karlan BY, Walsh C, Lester J, John EM, Whittemore AS, Daly MB, Southey M, Hopper J, Terry MB, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Steele L, Neuhausen SL, Ding YC, Hansen TV, Jønson L, Ejlertsen B, Gerdes AM, Infante M, Herráez B, Moreno LT, Weitzel JN, Herzog J, Weeman K, Manoukian S, Peissel B, Zaffaroni D, Scuvera G, Bonanni B, Mariette F, Volorio S, Viel A, Varesco L, Papi L, Ottini L, Tibiletti MG, Radice P, Yannoukakos D, Garber J, Ellis S, Frost D, Platte R, Fineberg E, Evans G, Lalloo F, Izatt L, Eeles R, Adlard J, Davidson R, Cole T, Eccles D, Cook J, Hodgson S, Brewer C, Tischkowitz M, Douglas F, Porteous M, Side L, Walker L, Morrison P, Donaldson A, Kennedy J, Foo C, Godwin AK, Schmutzler RK, Wappenschmidt B, Rhiem K, Engel C, Meindl A, Ditsch N, Arnold N, Plendl HJ, Niederacher D, Sutter C, Wa… See abstract for full author list ➔ Osorio A, et al. Among authors: evans g. PLoS Genet. 2014 Apr 3;10(4):e1004256. doi: 10.1371/journal.pgen.1004256. eCollection 2014 Apr. PLoS Genet. 2014. PMID: 24698998 Free PMC article.
Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK).
Pijpe A, Andrieu N, Easton DF, Kesminiene A, Cardis E, Noguès C, Gauthier-Villars M, Lasset C, Fricker JP, Peock S, Frost D, Evans DG, Eeles RA, Paterson J, Manders P, van Asperen CJ, Ausems MG, Meijers-Heijboer H, Thierry-Chef I, Hauptmann M, Goldgar D, Rookus MA, van Leeuwen FE; GENEPSO; EMBRACE; HEBON. Pijpe A, et al. Among authors: evans dg. BMJ. 2012 Sep 6;345:e5660. doi: 10.1136/bmj.e5660. BMJ. 2012. PMID: 22956590 Free PMC article.
Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined.
Heijnsdijk EA, Warner E, Gilbert FJ, Tilanus-Linthorst MM, Evans G, Causer PA, Eeles RA, Kaas R, Draisma G, Ramsay EA, Warren RM, Hill KA, Hoogerbrugge N, Wasser MN, Bergers E, Oosterwijk JC, Hooning MJ, Rutgers EJ, Klijn JG, Plewes DB, Leach MO, de Koning HJ. Heijnsdijk EA, et al. Among authors: evans g. Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1458-68. doi: 10.1158/1055-9965.EPI-11-1196. Epub 2012 Jun 28. Cancer Epidemiol Biomarkers Prev. 2012. PMID: 22744338
Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
Gronwald J, Robidoux A, Kim-Sing C, Tung N, Lynch HT, Foulkes WD, Manoukian S, Ainsworth P, Neuhausen SL, Demsky R, Eisen A, Singer CF, Saal H, Senter L, Eng C, Weitzel J, Moller P, Gilchrist DM, Olopade O, Ginsburg O, Sun P, Huzarski T, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group. Gronwald J, et al. Breast Cancer Res Treat. 2014 Jul;146(2):421-7. doi: 10.1007/s10549-014-3026-3. Epub 2014 Jun 21. Breast Cancer Res Treat. 2014. PMID: 24951267 Free PMC article.
2,698 results